🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Stifel maintains Buy on Outset Medical shares on multi-year hemodialysis agreement

EditorNatashya Angelica
Published 04/18/2024, 02:50 AM
OM
-

On Wednesday, Stifel reiterated its Buy rating on Outset Medical Inc. (NASDAQ:OM), with a stock price target of $6.00. Outset Medical announced a significant multi-year agreement with U.S. Renal Care to provide its Tablo hemodialysis system, which is expected to enhance home hemodialysis services in the United States.

The deal with U.S. Renal Care, a major dialysis care provider, is seen as a positive development for Outset Medical, particularly as it follows a period of challenges for the company, including concerns about the uptake of GLP-1 treatments affecting end-stage renal disease incidence, pending regulatory approvals, and a recent FDA reclassification of a Tablo product recall.

U.S. Renal Care operates approximately 500 dialysis centers, over 6,000 dialysis stations, and around 100 home programs, ranking as the third-largest dialysis clinic operator in the U.S. The agreement is anticipated to be a positive sales driver for Outset Medical starting in 2025, although the specific financial impact of the Tablo system placements was not disclosed.

The industry is looking forward to more details, which are likely to be revealed when Outset Medical reports its first-quarter 2024 results in early May.

The partnership is a clear endorsement of the Tablo system's value proposition and signifies Outset's ongoing efforts to expand home hemodialysis care in the U.S.

While the company faces ongoing issues, such as awaiting the final clearance for its TabloCart with Prefiltration 510K expected in mid-2024, the agreement with U.S. Renal Care is considered a positive step that could contribute to regaining momentum for Outset Medical's shares throughout the year.

InvestingPro Insights

As Outset Medical Inc. (NASDAQ:OM) secures a promising deal with U.S. Renal Care, there are several financial metrics and InvestingPro Tips that can provide investors with a deeper understanding of the company's current market position.

With a reduced market capitalization of $116.85 million, the company's stock price has experienced significant volatility, as evidenced by a 16.59% return over the last month, contrasting with an 85.83% decline over the last year.

This volatility is an important consideration for investors, as reflected in the InvestingPro Tips, which highlight the company's challenges, including a quick cash burn and the analysts' anticipation that the company will not be profitable this year.

Despite these challenges, the company's liquidity position appears robust, with liquid assets that exceed short-term obligations. This is a crucial factor for investors to consider, especially as the company navigates through its current operational hurdles.

Moreover, Outset Medical trades at a low revenue valuation multiple, which could present an opportunity for investors looking for potential growth at a discounted price, especially in light of the new partnership that could drive future sales.

Investors interested in Outset Medical may find additional insights and metrics on InvestingPro. There are currently 11 more InvestingPro Tips available, which can be accessed with the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription. These tips could further guide investment decisions, especially as the market anticipates Outset Medical's first-quarter 2024 results and more details about the financial impact of the Tablo system placements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.